The Effect of Methylation on the Let-7-BCL2L1-BCL2 Axis and the Potential Use of Hypomethylating and BH3 Mimetic Drugs in Histiocytic Neoplasms

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2024 Nov 8

PMID 39516372

Authors

Mali Salmon-Divon

Refael Meyuchas

Ofer Shpilberg

Elimelech Okon

Jamal Benhamida

Mariko Yabe

Kseniya Petrova-Drus

Tal Zvida-Bloch

May Basood

Roei Mazor

Benjamin H Durham

Julien Haroche

Omar Abdel-Wahab

Eli L Diamond

Oshrat Hershkovitz-Rokah

Affiliations

Soon will be listed here.

References

Goyal G, Tazi A, Go R, Rech K, Picarsic J, Vassallo R . International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022; 139(17):2601-2621. PMC: 11022927. DOI: 10.1182/blood.2021014343. View

Durham B, Hershkovitz-Rokah O, Abdel-Wahab O, Yabe M, Chung Y, Itchaki G . Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. Blood Adv. 2023; 7(23):7319-7328. PMC: 10711187. DOI: 10.1182/bloodadvances.2022009349. View

Goyal G, Heaney M, Collin M, Cohen-Aubart F, Vaglio A, Durham B . Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020; 135(22):1929-1945. DOI: 10.1182/blood.2019003507. View

Diamond E, Francis J, Lacouture M, Rotemberg V, Yabe M, Petrova-Drus K . CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. Leukemia. 2023; 37(8):1737-1740. PMC: 10400417. DOI: 10.1038/s41375-023-01947-4. View

Durham B . Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol. 2018; 86:62-76. DOI: 10.1016/j.semcdb.2018.03.002. View

Yan Y, Xie R, Zhang Q, Zhu X, Han J, Xia R . Bcl-x/Bak interaction and regulation by miRNA let-7b in the intrinsic apoptotic pathway of stored platelets. Platelets. 2017; 30(1):75-80. DOI: 10.1080/09537104.2017.1371289. View

Nishiyama A, Nakanishi M . Navigating the DNA methylation landscape of cancer. Trends Genet. 2021; 37(11):1012-1027. DOI: 10.1016/j.tig.2021.05.002. View

Weissman R, Diamond E, Haroche J, Pillar N, Shapira G, Durham B . The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers (Basel). 2020; 12(11). PMC: 7693724. DOI: 10.3390/cancers12113240. View

Kramer A, Green J, Pollard Jr J, Tugendreich S . Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2013; 30(4):523-30. PMC: 3928520. DOI: 10.1093/bioinformatics/btt703. View

10.

Weissman R, Diamond E, Haroche J, Durham B, Cohen F, Buthorn J . MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia. 2021; 36(4):1139-1149. PMC: 8979810. DOI: 10.1038/s41375-021-01472-2. View

11.

Pegoraro F, Maniscalco V, Peyronel F, Westenend P, Hendriksz T, Roperto R . Long-term follow-up of mTOR inhibition for Erdheim-Chester disease. Blood. 2020; 135(22):1994-1997. DOI: 10.1182/blood.2019004478. View

12.

Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M . TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology (Oxford). 2013; 53(1):198-200. DOI: 10.1093/rheumatology/ket246. View

13.

Mazor R, Weissman R, Luckman J, Domachevsky L, Diamond E, Abdel-Wahab O . Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neurooncol Adv. 2020; 2(1):vdaa024. PMC: 7212923. DOI: 10.1093/noajnl/vdaa024. View

14.

Nishi M, Eguchi-Ishimae M, Wu Z, Gao W, Iwabuki H, Kawakami S . Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements. Leukemia. 2012; 27(2):389-97. DOI: 10.1038/leu.2012.242. View

15.

Hogstad B, Berres M, Chakraborty R, Tang J, Bigenwald C, Serasinghe M . RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2017; 215(1):319-336. PMC: 5748846. DOI: 10.1084/jem.20161881. View